Assessment of Enterovirus Excretion and Identification of VDPVs in Patients with Primary Immunodeficiency in India: Outcome of ICMR–WHO Collaborative Study Phase-I
Madhu Chhanda Mohanty,
Mukesh Desai,
Ahmad Mohammad,
Amita Aggarwal,
Geeta Govindaraj,
Sagar Bhattad,
Harsha Prasada Lashkari,
Liza Rajasekhar,
Harish Verma,
Arun Kumar,
Unnati Sawant,
Swapnil Yashwant Varose,
Prasad Taur,
Reetika Malik Yadav,
Manogat Tatkare,
Mevis Fernandes,
Umair Bargir,
Sanjukta Majumdar,
Athulya Edavazhippurath,
Jyoti Rangarajan,
Ramesh Manthri,
Manisha Ranjan Madkaikar
Affiliations
Madhu Chhanda Mohanty
Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India
Mukesh Desai
Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai 400012, India
Ahmad Mohammad
World Health Organization, Country Office, New Delhi 110011, India
Amita Aggarwal
Department of Clinical Immunology & Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
Geeta Govindaraj
Department of Pediatrics, Government Medical College, Kozhikode 673008, India
Sagar Bhattad
Department of Pediatrics, Aster CMI Hospital, Bangalore 560092, India
Harsha Prasada Lashkari
Department of Pediatrics, Kasturba Medical College, Mangalore 576104, India
Liza Rajasekhar
Department of Clinical Immunology and Rheumatology, Nizam’s Institute of Medical Sciences, Hyderabad 500082, India
Harish Verma
World Health Organization, CH-1211 Geneva, Switzerland
Arun Kumar
World Health Organization, Country Office, New Delhi 110011, India
Unnati Sawant
Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India
Swapnil Yashwant Varose
Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India
Prasad Taur
Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai 400012, India
Reetika Malik Yadav
ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India
Manogat Tatkare
Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India
Mevis Fernandes
Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India
Umair Bargir
ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India
Sanjukta Majumdar
Department of Clinical Immunology & Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
Athulya Edavazhippurath
Multidisciplinary Research Unit, Government Medical College, Kozhikode 673008, India
Jyoti Rangarajan
Department of Pediatrics, Aster CMI Hospital, Bangalore 560092, India
Ramesh Manthri
Department of Clinical Immunology and Rheumatology, Nizam’s Institute of Medical Sciences, Hyderabad 500082, India
Manisha Ranjan Madkaikar
ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India
The emergence of vaccine-derived polioviruses (VDPVs) in patients with Primary Immunodeficiency (PID) is a threat to the polio-eradication program. In a first of its kind pilot study for successful screening and identification of VDPV excretion among patients with PID in India, enteroviruses were assessed in stool specimens of 154 PID patients across India in a period of two years. A total of 21.42% of patients were tested positive for enteroviruses, 2.59% tested positive for polioviruses (PV), whereas 18.83% of patients were positive for non-polio enteroviruses (NPEV). A male child of 3 years and 6 months of age diagnosed with Hyper IgM syndrome was detected positive for type1 VDPV (iVDPV1) with 1.6% nucleotide divergence from the parent Sabin strain. E21 (19.4%), E14 (9%), E11 (9%), E16 (7.5%), and CVA2 (7.5%) were the five most frequently observed NPEV types in PID patients. Patients with combined immunodeficiency were at a higher risk for enterovirus infection as compared to antibody deficiency. The high susceptibility of PID patients to enterovirus infection emphasizes the need for enhanced surveillance of these patients until the use of OPV is stopped. The expansion of PID surveillance and integration with a national program will facilitate early detection and follow-up of iVDPV excretion to mitigate the risk for iVDPV spread.